English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduFOR IMMEDIATE RELEASE
Media Contact: Monica McDonald
Office – (404) 633-3777 ext. 332
Osteoarthritis (OA) is a common joint disease that most often affects middle-age to elderly people. It used to be commonly referred to as “wear and tear” of the joints, but we now know that OA is a disease of the entire joint, involving the cartilage, joint lining, ligaments, and bone.
Vitamin K deficiency has been associated with OA, and recent research shows that vitamin K supplementation may reduce OA progression. However, no studies to date have evaluated whether vitamin K antagonism with the use of warfarin, an anticoagulant drug, can be detrimental to OA. This new study evaluated the relationship of warfarin, a medication commonly prescribed for atrial fibrillation—which is the management of quivering or irregular heartbeats—to the risk of knee and hip replacements in end-stage OA.
“We hypothesized that disruption of the functioning of vitamin K-dependent bone and cartilage proteins through vitamin K antagonism may lead to abnormalities in chondrocyte functioning with adverse effects on cartilage health, which in turn can increase the risk of developing or worsening of OA,” says study co-author Priyanka Ballal, MD, Rheumatology Fellow at Boston University Medical Center. “Because direct oral anti-coagulants are alternate options for anticoagulation that do not inhibit vitamin K’s functioning, clarifying this risk of warfarin would give providers and patients valuable information when they consider their choice of anticoagulation in patients with atrial fibrillation.”
The nested, case-control study used data from the Health Improvement Network, a general practitioner-based electronic medical records database from the United Kingdom (UK) that is representative of the general population. The study sample was limited to adults ages 40-89 with atrial fibrillation since this diagnosis warrants anticoagulation therapy. They compared warfarin, which is a vitamin K antagonist, with direct oral anticoagulants which do not inhibit vitamin K and were first marketed in the UK in 2008. Among other exclusions, they excluded anyone who had a knee or hip replacement before 2014, anyone with severe comorbidities that would limit surgery, those who took warfarin or direct oral anticoagulants within one year prior to the study period, and anyone who used both drugs in the study period. They identified cases as anyone who had a knee or hip replacement between 2014 and 2018. Each case was matched with up to four controls for age and gender. Warfarin and direct oral anticoagulant use were defined as having one or more prescriptions after the study entry and within one year before the index date.
The researchers assessed how warfarin compared with direct oral anticoagulants for the risk of knee or hip replacements. The study included 913 patients who had either knee or hip replacement, age- and gender-matched four-to-one with 3,652 controls. Their mean age was 74 and 46% were female. Of the 913 surgery cases, 64.9% were warfarin users and 35.1% were direct oral anticoagulant users.
After adjusting for potential confounders, they found that warfarin users had 1.57 times higher odds of having a knee replacement or hip replacement than direct oral anticoagulant users. They also found an increasing risk of knee or hip replacement surgery with the duration of warfarin use compared to direct oral anticoagulants use.
The researchers stress that their data supports the importance of adequate vitamin K in limiting the progression of OA in patients and raises the consideration of using direct oral anticoagulants instead of warfarin when indicated in people with OA or at risk for the disease.
“Our research supports the importance of adequate Vitamin K and dependent proteins for limiting progression of OA,” says Dr. Ballal. “Given these potential adverse effects of warfarin on joint health, our study suggests that direct oral anticoagulants could be considered for managing atrial fibrillation among patients who have OA. The next steps for our group’s research are the design and launch of an adequately powered randomized trial to test the efficacy of vitamin K supplementation for OA outcomes.”
About ACR Convergence
ACR Convergence, the ACR’s annual meeting, is where rheumatology meets to collaborate, celebrate, congregate, and learn. Join ACR for an all-encompassing experience designed for the entire rheumatology community. ACR Convergence is not just another meeting – it’s where inspiration and opportunity unite to create an unmatched educational experience. For more information about the meeting, visit https://www.rheumatology.org/Annual-Meeting, or join the conversation on Twitter by following the official hashtag (#ACR20).
About the American College of Rheumatology
The American College of Rheumatology (ACR) is an international medical society representing over 7,700 rheumatologists and rheumatology health professionals with a mission to empower rheumatology professionals to excel in their specialty. In doing so, the ACR offers education, research, advocacy and practice management support to help its members continue their innovative work and provide quality patient care. Rheumatologists are experts in the diagnosis, management and treatment of more than 100 different types of arthritis and rheumatic diseases.
ABSTRACT: Warfarin Use and Risk of Knee and Hip Replacements
Background/Purpose:
Vitamin K is an essential co-factor in the post-translational gamma-carboxylation of glutamic acid to form gamma-carboxy-glutamic acid (Gla) residues. This confers functionality to vitamin K-dependent proteins including those in bone and cartilage that play an important role in regulating mineralization. Low vitamin K can lead to under-carboxylation of Gla proteins and thus their dysfunction. Vitamin K deficiency has been associated with OA, and a randomized trial of vitamin K supplementation demonstrated trends towards less OA progression. Studies to date have not evaluated whether vitamin K antagonism with warfarin can be detrimental to OA. We therefore evaluated the relation of warfarin to risk of knee and hip replacements as a reflection of end-stage OA.
Methods:
We conducted a nested case-control study using The Health Improvement Network, a general practitioner (GP)-based electronic medical records database from the UK that is representative of the general population. To minimize confounding by indication, we limited our study sample to adults (aged 40-89) with atrial fibrillation, as this diagnosis warrants therapy with anticoagulation. Additionally, we compared warfarin, a vitamin K antagonist, with direct oral anticoagulants (DOAC), which are not vitamin K antagonists. Because DOACs were first marketed in the UK in 2008, we limited our study to those who had been enrolled for ≥1 year with a GP between 2009 and 2018. We excluded individuals with knee or hip replacement (KR/HR) prior to 2014, severe co-morbidities that would limit surgery, those with warfarin or DOAC use within 1 year prior to our study period, and those who used both drugs during study period. We identified cases as those with KR or HR between 2014-2018, with surgery date being the index date for cases. Each case was matched with up to 4 controls by age and gender. We defined warfarin and DOAC use as having ≥1 prescription after study entry and within 1 year prior to the index date. We assessed the relation of warfarin compared with DOAC use to risk of KR or HR using conditional logistic regression, adjusting for potential confounders.
Results:
We identified 913 subjects with KR or HR (cases) who were age and gender-matched 4:1 with 3652 controls (mean age 74, 46% female). Of the 913 cases, 64.9% were warfarin users while 35.1% were DOAC users; in contrast, of the 3652 controls, 56.3% were warfarin users while 43.6% were DOAC users. With adjustment for potential confounders, warfarin users had 1.57 times higher odds of KR or HR than DOAC users (Adjusted OR 1.57, 95% CI (1.30-1.89)) (Table). When matched by practice ID to account for practice variation, we found a slightly diminished but significant association (Adjusted OR 1.25, 95% CI (1.03-1.52)). There was increasing risk of KR or HR with duration of warfarin vs. DOAC exposure (Figure).
Conclusions:
Warfarin use, a vitamin K antagonist, was associated with significantly greater risk of KR or HR (an indicator for end-stage knee OA) than DOAC use, with risk increasing with duration of use. These data add further support to the importance of adequate vitamin K and its dependent proteins in limiting progression of OA and raises the consideration of using DOACs over warfarin when indicated in those with or at risk of OA.
